Research programme: beta-thalassaemia gene therapy - AvigenAlternative Names: Beta-thalassaemia gene therapy with erythropoietin - Avigen
Latest Information Update: 07 Sep 2005
At a glance
- Originator Avigen
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thalassaemia
Most Recent Events
- 27 Jun 2005 Discontinued - Preclinical for Thalassaemia in USA (unspecified route)
- 19 Mar 2003 Suspended - Preclinical for Thalassaemia in USA (unspecified route)
- 09 Jul 2001 This programme is still in active development